3D Bioprinting of Cellular Therapeutic Systems in Ophthalmology: from Bioengineered Tissue to Personalized Drug Delivery
Kim H., Ngo GH., Hong W., Lee SH., Mahajan VB., DeBoer C.
Narrative Review, published in Curr Ophthalmol Rep (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Curr Ophthalmol Rep (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41019312
- PMCID
- PMC12474738
- DOI
- 10.1007/s40135-025-00337-6
- Citations
- 1
Abstract (original English)
Purpose of review In this article, we provide a brief overview of 3D bioprinting technologies and the types of cells employed in ophthalmic cell therapy. We then explore recent applications of 3D bioprinting in ophthalmic cell delivery systems. Recent findings Cell therapy in ophthalmology is a promising treatment for various eye diseases, there exists some limitations of existing cell therapy strategies Such as cell loss, poor integration with Surrounding tissues, and the sustainability of long-term effects. In this regard, 3D bioprinting technology provides a beneficial method for developing highly biomimetic and reliable cell delivery systems for ophthalmic disease research. Recent advances have shown bioengineered tissues which replicate the microstructure of native tissues, personalized ophthalmic devices, and encapsulated cell-delivery systems. While still in the early stages of advancement, the development of cell delivery systems based on bioprinting technologies is indeed inspiring and has the potential to be applied to other ocular diseases. Summary Cell therapy based on 3D bioprinting technology in ophthalmology has great potential in ophthalmic disease treatment as well as ocular tissue engineering and regenerative medicine.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.